AstraZeneca news in 2026: 25 dated events
The latest AstraZeneca event on this page is dated Sep 29, 2026. proactiveinvestors.com reported: AstraZeneca invests $2 billion in Summit Therapeutics in cancer drug deal.
PublicConsumer Services10,000+ employeesastrazeneca.comLinkedIn
- Dated events
- 25
- Last 90 days
- 25
- Latest
- Sep 29, 2026
News · latest 10
Latest AstraZeneca news
Showing 10 of 25 dated events. The Signal API returns all of them.
Get them with one API call- AstraZeneca invests $2 billion in Summit Therapeutics in cancer drug dealWith Summit Therapeutics Inc.
- Multiply Labs Raises $75M in Series B Funding to Scale Robotic Drug ManufacturingAstraZeneca Ventures participated in Multiply Labs' $75 million Series B funding round.
- AstraZeneca shares oversold after trial flops and merger talk, says UBSAstraZeneca has recently invested $15 billion in China to support its ambition of reaching $80 billion in revenue.
- New drug shows promise in reducing COPD symptoms in former and current smokers, clinical trials show - ABC News - Breaking News, Latest News and VideosAstraZeneca is developing tozorakimab, a first-in-class monoclonal antibody, which has shown promise in late-stage clinical trials for reducing COPD symptoms in smokers and former smokers.
- Assessment of the Rheumatoid Arthritis Market 2026-2036 Featuring Rise Therapeutics, Taiho Pharmaceutical, Abbvie, Eli Lilly/Incyte, and AstraZenecaAstraZeneca is developing AZD1163, a rheumatoid arthritis drug candidate which has advanced to Phase II clinical trials.
- AstraZeneca Secures FDA Nod for New Breast Cancer Therapy EtcamahAstraZeneca is evaluating its breast cancer drug Etcamah in several phase III studies (SERENA-4, CAMBRIA-1, CAMBRIA-2) to potentially expand its use as both a monotherapy and in combination treatments.
- AstraZeneca’s Breast Cancer Drug Etcamah Gets US FDA ApprovalAstraZeneca received FDA approval for its breast cancer drug, camizestrant, which will be marketed under the brand name Etcamah.
- C4X Discovery to receive milestone payment for NRF2 exclusive worldwide license agreementAstraZeneca is advancing AZD4916, an oral NRF2 activator licensed from C4X Discovery, into a Phase I study for the treatment of inflammatory and respiratory diseases.
Showing 10 of 25 dated events. The Signal API returns all of them.
Get them with one API callSignal API · MCP
Track AstraZeneca with the Signal API
One POST /v1/companies/enrich call with astrazeneca.com returns AstraZeneca news signals (news), each with its source. Or ask Claude through MCP.
2 credits per signal returned; zero-result calls are free. Endpoint reference
curl -X POST https://signals.autobound.ai/v1/companies/enrich \
-H "X-API-KEY: $AUTOBOUND_API_KEY" \
-H "Content-Type: application/json" \
-d '{"domain":"astrazeneca.com","signal_types":["news"],"limit":20}'Same industry
News at related companies
Questions about AstraZeneca news
What is the latest news on AstraZeneca?
What is going on with AstraZeneca?
Source. News articles about the company, one source link per event.
Method. Stories about the same event within 14 days merge into one row. Noise (lists, stock tips, recaps) is removed.
Data as of .